High-risk patent foramen ovale and elderly in cryptogenic stroke
- PMID: 37722223
- DOI: 10.1016/j.jstrokecerebrovasdis.2023.107344
High-risk patent foramen ovale and elderly in cryptogenic stroke
Abstract
Background: High-risk patent foramen ovale (PFO) could be pathological in cryptogenic stroke (CS), but its clinical characteristics have not been fully studied, especially in elderly patients.
Methods: Patients with CS were enrolled in the CHALLENGE ESUS/CS registry, a multicenter registry of CS patients undergoing transesophageal echocardiography. Clinical characteristics were compared among three groups: high-risk PFO group, large shunt PFO (≥25 microbubbles) or PFO with atrial septal aneurysm (ASA); right-to-left shunt (RLS) group, RLS including PFO with <25 microbubbles or without ASA; and no-RLS group.
Results: In total, 654 patients were analyzed: 91, 221, and 342 in the high-risk PFO, RLS, and no-RLS groups, respectively. In multinomial logistic regression analysis, the male sex (odds ratio [OR] 1.825 [1.067-3.122]) was independently associated with high-risk PFO, but hypertension (OR, 0.562 [0.327-0.967]), multiple infarctions (OR, 0.601 [0.435-0.830]), and other cardioaortic embologenic risks (OR, 0.514 [0.294-0.897]) were inversely associated with high-risk PFO compared with non-RLS. In 517 patients aged ≥60 years, multiple infarctions (OR, 0.549 [0.382-0.788]) and other cardioaortic embologenic risks (OR, 0.523 [0.286-0.959]) were inversely associated with high-risk PFO.
Conclusions: High-risk PFO had specific clinical characteristics and possible mechanistic associations, and this trend was consistent among CS patients aged ≥60 years.
Clinical trial registration information: http://www.umin.ac.jp/ctr/ (UMIN000032957).
Keywords: Cryptogenic stroke; Embolic stroke of undetermined source; Patent foramen ovale; Transesophageal echocardiography.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest YU received lecture fees from OHARA Pharmaceutical Co., Ltd., and research funds from Bristol-Myers Squibb. HT received lecture fees from Pfizer Japan Inc. and Daiichi Sankyo Co., Ltd. MK received lecture fees from Bayer Pharmaceutical Co. YK received personal fees from Daiichi Sankyo Co., Ltd., and grants from Bristol-Myers Squibb and Nippon Boehringer Ingelheim, Co., Ltd. MI received a research grant from Shimadzu Corporation, Otsuka Pharmaceutical, and Panasonic Corporation, and lecture fees from Daiichi Sankyo Co., Ltd., Eisai Co. Ltd. Bayer Pharmaceutical Co. KH received lecture fees from MSD Co., Ltd., Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Pfizer Japan Inc., Novartis Pharma K.K., and AbbVie GK, Kyowa Hakko-Kirin Co., Eli Lilly Japan K.K, Amgen K.K., and Lundbeck Japan K.K., and research funds from Eisai Co., Ltd., Pfizer Japan Inc., Novartis Pharma K.K., Takeda Pharmaceutical Co., Ltd., TAIYO Co., Ltd., Kyowa Minami Hospital, Shirasawa Hospital, Shiobara Onsen Hospital, Utsunomiya Chuo Hospital, Nishikata Hospital, and Moka Hospital. YH received lecture fees from Bayer Pharmaceutical Co. and Nippon Boehringer Ingelheim, Co., Ltd. NH was an advisory member of Dai-Nippon Sumitomo Pharma Co., Ltd., Hisamitsu Pharmaceutical Co., Inc, Biogen Idec Japan Ltd., received lecture fees from Dai-Nippon Sumitomo Pharma Co., Ltd., Otsuka Pharmaceutical, Co., Ltd., Takeda Pharmaceutical Co., Ltd., Kyowa Hakko-Kirin Co., Ltd., FP Pharmaceutical Corporation, Eisai Co., Ltd., and Novartis Pharma K.K., AbbVie, and received departmental endowments by commercial entities from Kyowa Hakko-Kirin Co., Ltd., Nippon Boehringer Ingelheim, Co., Ltd., AbbVie GK, FP Pharmaceutical Corporation, Otsuka Pharmaceutical, Co., Ltd., Dai-Nippon Sumitomo Pharma Co., Ltd., Eisai Co., Ltd., Nihon Medi-physics Co., Ltd., Asahi Kasei Medical Co., Ltd., Ono Pharmaceutical Co., Ltd., MiZ Co., Ltd., AbbVie GK, OHARA Pharmaceutical Co., Ltd., Nihon Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Boston Scientific Corporation, and Medtronic Inc. TU received lecture fees from Daiichi Sankyo Co., Ltd., Boehringer Ingelheim, Otsuka Pharmaceutical Co., Ltd., Bayer Pharmaceutical Co., and AstraZeneca K.K., and research funds from Otsuka Pharmaceutical Co., Ltd., and AbbVie GK.
LinkOut - more resources
Full Text Sources
